Literature DB >> 17015021

Genomics and proteomics: emerging technologies in clinical cancer research.

Christine H Chung1, Shawn Levy, Pierre Chaurand, David P Carbone.   

Abstract

Fueled by the complete genomic data acquired from the human genome project and the desperate clinical need of comprehensive analytical tools to study a heterogeneous disease like cancer, genomic and proteomic technologies have evolved rapidly, accelerating the rate and number of discoveries in clinical cancer research. These discoveries include mechanistic understanding of cancer biology as well as the identification of biomarkers supporting early detection, molecular classification of tumors, molecular predictors of metastasis, treatment response, and prognosis. While the technical advances have been significant, clinical researchers and practicing physicians are now confronted with the challenges of understanding technically and statistically complex data sets, translating this complex information to fit clinical contexts and incorporating it into clinical studies. In this review, we will summarize the available technologies and associated bioinformatics, discuss studies that are clinically relevant, and discuss the limitations we are still facing. We will present a framework for future directions of these technologies and how we believe they should be applied in clinical studies.

Entities:  

Mesh:

Year:  2006        PMID: 17015021     DOI: 10.1016/j.critrevonc.2006.06.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  13 in total

Review 1.  Laser capture microdissection: Big data from small samples.

Authors:  Soma Datta; Lavina Malhotra; Ryan Dickerson; Scott Chaffee; Chandan K Sen; Sashwati Roy
Journal:  Histol Histopathol       Date:  2015-04-20       Impact factor: 2.303

2.  SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Authors:  Primo N Lara; James Moon; Paul J Hesketh; Mary W Redman; Stephen K Williamson; Wallace L Akerley; Fred R Hirsch; Philip C Mack; David R Gandara
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

3.  Spatial mapping by imaging mass spectrometry offers advancements for rapid definition of human skin proteomic signatures.

Authors:  Domenico Taverna; Lillian B Nanney; Alonda C Pollins; Giovanni Sindona; Richard Caprioli
Journal:  Exp Dermatol       Date:  2011-05-04       Impact factor: 3.960

4.  Ezrin expression and cell survival regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ashwani Rajput; Michelle Mathiesen; Ekta Agarwal; Audrey J Lazenby; Chandrakanth Are; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

Review 5.  Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity.

Authors:  Manfred Kunz; Saleh M Ibrahim
Journal:  Mediators Inflamm       Date:  2009-10-26       Impact factor: 4.711

Review 6.  Institutional shared resources and translational cancer research.

Authors:  Paolo De Paoli
Journal:  J Transl Med       Date:  2009-06-29       Impact factor: 5.531

Review 7.  Genomic analysis of epithelial ovarian cancer.

Authors:  John Farley; Laurent L Ozbun; Michael J Birrer
Journal:  Cell Res       Date:  2008-05       Impact factor: 25.617

8.  Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program.

Authors:  Christine H Chung; Stuart Wong; K Kian Ang; Elizabeth H Hammond; Adam P Dicker; Paul M Harari; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007       Impact factor: 7.038

9.  Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing.

Authors:  Fiona A Miller; Paul Krueger; Robert J Christensen; Catherine Ahern; Ronald F Carter; Suzanne Kamel-Reid
Journal:  BMC Health Serv Res       Date:  2009-07-30       Impact factor: 2.655

10.  Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.

Authors:  K Nishimura; Y Tsuchiya; H Okamoto; K Ijichi; M Gosho; M Fukayama; K Yoshikawa; H Ueda; C R Bradford; T E Carey; T Ogawa
Journal:  Br J Cancer       Date:  2014-07-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.